Four offers. $42.25, $44, $47, $47.50 per share. Each rejected until the last. The difference between offer #3 and offer #4? Fifty cents — but on 346.7 million shares, that’s $173 million.
At what point do you walk away? And how do you know if you overpaid?
In Post 8, we learned WHY Thermo Fisher wanted PPD — to fill the CRO gap and create an end-to-end drug development platform. But wanting something and knowing what to pay for it are very different problems. HP wanted Autonomy too — and paid $11 billion for a company that was worth a fraction of that. Kraft wanted Heinz’s synergies — and wrote down $15.4 billion when they didn’t materialize.
This post follows the PPD deal from first contact to the 2.5-year verdict. You’ll learn how Parker’s team valued PPD, calculated synergies, survived four rounds of negotiation, and what $17.4 billion actually bought. Then we’ll check: was it worth it?
- You want to see how a real $17B acquisition is valued from the inside
- You want to understand what goodwill and intangible assets actually mean
- You want to learn why some M&A deals succeed while others become cautionary tales
Imagine buying a house. You don’t just look at the asking price — you hire an inspector, check the foundation, review the neighborhood, understand the HOA rules. Now imagine buying a house with 25,000 people living in it, all of whom might leave if they don’t like the new owner.
That’s acquiring a service company.
Unlike buying a factory where value is in the equipment, buying a CRO means buying people. If they leave, you bought an empty shell. So before Parker’s team even talked price, they had to answer a deeper question: is PPD the right fit?
The Cultural Assessment
One of the first things Parker did was examine PPD’s website — their mission, values, and corporate culture. He needed to know whether PPD would fit within Thermo Fisher’s mission, vision, and corporate culture.
The result? A strong match. PPD was focused on helping the world create advanced therapeutics to defeat COVID and other pandemics, and develop life-saving drugs — something critically important to Thermo Fisher as well. The culture fit was strong, and the business fit seemed equally promising.
PPD had a strong biotechnology base that aligned with Thermo Fisher’s operations. Parker felt they could serve not only PPD’s biotech customers but also their large pharmaceutical company base, which dovetailed extremely well with Thermo Fisher’s customer base. And PPD served all of the top 50 global biopharma companies — a customer base that was itself a multi-billion-dollar asset.
Due Diligence: Business + Functional
But cultural fit is just the beginning. Parker’s team ran two parallel tracks of due diligence:
Business due diligence focused on the company’s future: projections, synergy targets, intellectual property, operations, and the type of rights they might have. A lot of time was spent here, often in conjunction with business units and outside consultants.
Functional due diligence focused on whether the two companies could actually be combined: HR policies, IT systems, cybersecurity, real estate, accounting, tax, legal, quality controls, and regulatory alignment. As Parker put it: “With over 130,000 employees, we can’t have 20 different HR policies. We need to think about how that can be more consistent over time.”
Every company sets up its policies and procedures differently. If the gap is too wide, integration becomes a nightmare. Parker’s team needed to assess not just what PPD was, but whether it could become part of Thermo Fisher without “doing harm” to the acquired company.
Business Due Diligence:
- Financial projections and growth trajectory
- Synergy targets — where will cost savings and revenue gains come from?
- Intellectual property and proprietary rights
- Operational capabilities and capacity
- Competitive positioning and market share
- Customer concentration risk (who are the key accounts?)
Functional Due Diligence:
- HR policies — compensation structure, turnover rates, talent retention plans
- IT systems — compatibility, migration complexity
- Cybersecurity posture — vulnerabilities, compliance
- Real estate — offices, labs, lease terms
- Accounting and tax policies — differences that could cause post-merger surprises
- Legal and regulatory compliance — industry-specific requirements
- Quality controls — standards alignment across organizations
Key questions to ask the target’s team:
- Compensation: How is compensation structured? What’s the turnover rate? (Goal: ensure core scientists and project managers won’t leave after the merger)
- Decision-making: Does the team have autonomy, or must they always get approval? (Goal: assess agility while maintaining safety standards)
- Collaboration: How do clinical teams work with manufacturing partners? (Goal: validate the synergy assumption that they’ll work well together)
Parker’s team spent months on this process. PPD rejected Thermo Fisher’s first two offers while due diligence was still underway. But as we’ll see in Part 6, each rejection actually helped both sides understand what a fair deal looked like.
Imagine you’re at an auction for a painting. Before you bid, you need to know five things:
- What’s the painting worth to a museum that just hangs it? (Standalone value)
- What’s it worth to YOU specifically — maybe you own the companion piece? (Integrated value)
- What if the colors are fading? (Sensitivity analysis)
- Will you get your money back? (Return on investment)
- Who else is bidding? (Competition)
That’s Parker’s 5-step process for valuing an acquisition target. Each step builds on the last, and skipping any one of them is how companies end up overpaying.
Step 1: Standalone Projection
What is PPD worth if nothing changes? The team starts by establishing the target’s own growth trajectory — using Wall Street research, outside advisers, and eventually the target’s own management projections. Parker notes a critical caveat: “Managements, when they either sell themselves or are asked to talk about being acquired, put a fairly promising set of projections out. So the team needs to take a critical eye as to what the real prospects of the business are.”
Step 2: Integrated Projection
What is PPD worth inside Thermo Fisher? This is where synergies enter the picture — cost savings from eliminating overlap, revenue gains from cross-selling. But also negative synergies: integration costs, potential culture clashes, investments needed to make the combination work.
Step 3: Sensitivity Analysis
What if growth is slower? Margins lower? The team applies upside and downside scenarios to stress-test assumptions. Parker emphasizes that this is where discipline matters: “What happens if there’s a downside scenario? How do key inputs like inflation, taxes, or other things change the analysis?”
Step 4: ROIC Calculation
Will the acquisition earn enough return on the capital invested? Parker sets a “fairly high bar” here, looking at a 5–7 year horizon. This is the financial discipline check — does the price being paid generate returns that justify the investment? As Parker puts it: “Ultimately, as a company, Thermo Fisher is generally acquiring something that it intends to keep forever. So we need to make sure that financial returns are reflective of that.”
Step 5: Bidding Competition
Who else might bid? In an auction, the team must assess how competitors would value the target and what their ability to pay looks like. In a one-on-one negotiation (like Thermo Fisher + PPD), the dynamics are different — but you still need to know your maximum price.
PPD’s Financial Snapshot
So what did PPD’s numbers actually look like? Here’s what Parker’s team was working with:
PPD was profitable but volatile — NOPAT dipped in 2020 due to COVID disruptions. Its equity was negative until the 2022 forecast (a legacy of its private equity history, not a sign of poor operations — as we explored in Post 8).
The critical metric was ROIC: 11.7% in 2020, forecast to reach 13.5% by 2023. Thermo Fisher’s own forecasts for PPD showed NOPAT growing from $485M (2021) to $593M (2023) — a confident bet that PPD would perform even better inside Thermo Fisher than it had alone.
Yes — both current (11.7%) and forecast (13.5%) ROIC exceed the 10% hurdle rate. But here’s the subtlety: the real test is whether PPD’s ROIC stays above the hurdle after paying the acquisition premium, which inflates the invested capital denominator.
If Thermo Fisher pays $17.4B for PPD (well above PPD’s book value of invested capital), the ROIC calculation uses the acquisition price as the invested capital base — which makes the bar much harder to clear. This is why Parker insists on a “fairly high bar” — the acquisition premium eats into returns.
There are two ways to price a used car. You can look at what similar cars sold for — comparable multiples. Or you can estimate how much value the car will deliver over its remaining life — fuel savings, reliability, fewer repairs — and calculate what that stream of value is worth today. That’s a discounted cash flow.
M&A valuation works the same way, just with more zeros.
Two Approaches to Valuing an Acquisition Target
Parker’s team used two main methods to value PPD:
PE Multiples — the “comparable cars” approach. Take the target’s forecasted earnings per share and multiply by a PE ratio. It’s quick but crude — and it comes in two flavors:
- Standalone: EPS forecast × pre-acquisition PE ratio (what the market currently values the company at)
- Acquirer’s view: Revised EPS (incorporating operational changes) × post-acquisition PE ratio
DCF / Abnormal Earnings — the “future value” approach. Calculate the present value of all future cash flows the target will generate. More precise, but heavily dependent on assumptions about growth, margins, and discount rates.
| Method | Standalone Value | Value to Acquirer |
|---|---|---|
| PE Multiples | EPS × pre-acquisition PE | Revised EPS × post-acquisition PE |
| DCF / Abnormal Earnings | PV of cash flows (no acquisition) | PV of cash flows + synergy benefits |
Here’s Parker’s critical insight: “If you pay all the way up to the DCF value, you’ve probably overpaid.” Why? Because DCF gives you the standalone intrinsic value. The synergies — which are the reason you’re acquiring — represent additional value that should justify the premium. If you pay full DCF for standalone value AND a premium on top, you’ve eaten into your synergy gains.
The Value Creation Formula
Here’s a simple example: if the value you receive (intrinsic value + synergies) is $675 and the price you pay (market value + premium) is $625, the value creation is ($675 − $625) / $625 = 8%. Not bad. But if the premium is too high or the synergies don’t materialize, that number goes negative — fast.
Acquisition Premiums: What’s Normal?
The acquisition premium — the extra amount paid above the target’s market price — typically ranges from 30% to 60% historically. Some landmark deals:
PPD’s 35% premium was on the lower end of historical norms — a sign of disciplined pricing by Parker’s team.
The Winner’s Curse
Here’s the uncomfortable truth about M&A: at least one-third of acquiring companies fail to create value. Academic research consistently shows that acquirers earn negative returns on average.
Why? The “winner’s curse.” In a competitive bidding process, the company that wins is often the one that overestimates synergies the most. They bid the highest because they believe in the most optimistic scenario — and then reality doesn’t cooperate.
This is why Parker’s five-step process matters: it’s a systematic defense against the winner’s curse. Every step — from standalone projections to sensitivity analysis to ROIC checks — is designed to prevent the team from overpaying.
Parker’s team built a detailed valuation model for PPD with the following key assumptions:
Revenue Growth Forecasts:
- Base Case: 13.3% → 12% → 9.1% → 10% → 10% (declining to a steady state)
- Upside Case: 16.8% → 10.2% → 11% → 12.2% → 12.3% (management’s optimistic view)
Key Margin Assumptions:
- NOPAT margin: 3-year historical average was 7.7%; model uses 9% (improvement expected post-integration)
- Net Working Capital / Sales: -10% (PPD collects cash before performing work — negative working capital is actually a strength)
- Net Operating Long-Term Assets / Sales: 77%
Market Data:
- Market price before first offer: $35/share
- Shares outstanding: 346.7 million
- This gives a pre-offer market cap of ~$12.1 billion
Note that management projections tend to be optimistic — Parker specifically warned about this. The team’s job is to apply “a critical eye” to ensure projections reflect reality, not wishful thinking.
DCF gives the standalone intrinsic value — what the company is worth on its own. The synergies, which are the entire reason for acquiring, represent additional value that needs to justify the premium.
If you pay full DCF for standalone value AND a premium on top, you’ve eaten into your synergy gains. The premium should come from the synergy upside, not from overpaying for the standalone business. Think of it this way: if synergies are worth $8/share and you pay the premium from that $8, you still capture value. But if you pay full standalone DCF plus a premium, the only way to create value is if synergies exceed what you already paid for them.
Think of synergies like moving in with a roommate. Cost synergies are obvious — you split the rent, utilities, and Netflix. Revenue synergies are harder — maybe your roommate’s network gets you a better job. The rent savings are guaranteed; the better job is speculative.
Now multiply by a billion.
Thermo Fisher projected $125 million in total annual synergies by the end of 2024, broken into two very different buckets:
Cost Synergies: $75 Million
These are the “split the rent” savings — the things you can control. Thermo Fisher identified $75 million in annual cost savings from:
- SG&A overlap: Redundant sales, general, and administrative functions between two large companies
- Public company costs eliminated: PPD was a publicly traded company. After acquisition, all the costs of being public (SEC filings, investor relations, independent board) disappear
- Redundant positions: Overlapping roles in back-office functions like finance, HR, and IT
Cost synergies are the safer bet. You control whether to close a redundant office or eliminate a duplicate role. Wall Street gives credit for these because they’re predictable.
Revenue Synergies: $50 Million Operating Income
These are the “better job from your roommate’s network” gains — speculative, but potentially more valuable. Thermo Fisher projected $150 million in new revenue, translating to $50 million in operating income, from:
- Cross-selling: PPD gets access to Thermo Fisher’s deep biopharma relationships. Suddenly, PPD’s CRO services can be offered to every Thermo Fisher customer who needs clinical trials
- End-to-end platform: The combined entity could offer drug discovery → clinical trials → manufacturing — something no competitor could match
Marc Casper, Thermo Fisher’s CEO, emphasized expanding the value proposition for biopharma customers — the ability to be a one-stop shop for drug development.
Why This Deal Was Different
Here’s what made the PPD acquisition unusual. Parker was explicit: “This was not a cost-synergy supported deal.”
Most acquisitions are justified primarily by cost synergies — the safe, predictable savings. This deal was betting on revenue synergies as the primary value driver. That’s unusual and risky. Wall Street typically doesn’t give much credit for revenue synergies because they’re speculative — customers decide whether to buy more, not the acquirer.
But Thermo Fisher had something most acquirers don’t: existing deep relationships with the exact customers PPD needed to reach. The cross-selling opportunity wasn’t theoretical — Thermo Fisher already had the accounts.
Valuing the Synergies
Because revenue synergies are “more speculative,” they require a higher discount rate when calculating their present value. More uncertainty = more risk = higher required return. This is conservative accounting — it reduces the present value of revenue synergies compared to the more certain cost synergies.
To calculate the present value of the synergies as a perpetuity (assuming they continue indefinitely): divide total annual synergies by the cost of equity, then divide by shares outstanding (346.7 million) to get the per-share synergy value.
Wall Street is skeptical of revenue synergies for good reason:
- Cost synergies = you control. You decide to close an office, lay off redundant staff, or consolidate IT systems. These are internal decisions.
- Revenue synergies = customers decide. You can offer cross-selling opportunities, but customers choose whether to buy. You can build an end-to-end platform, but customers choose whether to use it.
The history of M&A is littered with revenue synergy projections that never materialized. Companies announce “tremendous cross-selling opportunities” and then discover that customers don’t want a bundled offering, or that the sales teams can’t actually sell each other’s products.
Why this deal was different: Thermo Fisher already had strong strategic biopharma relationships. PPD’s CRO services could be offered to customers who already trusted and worked with Thermo Fisher. The cross-selling bridge wasn’t hypothetical — it was built on existing relationships. This is why analysts later noted that “Thermo Fisher’s customer base was embracing the end-to-end CRO market offering better than expected.”
Higher discount rate. More speculation = more risk = higher required return. This reduces the present value of revenue synergies compared to the more certain cost synergies.
It’s a conservative approach that protects against overvaluing uncertain gains. If revenue synergies don’t materialize, using a higher discount rate means you didn’t overpay as badly. If they do materialize, you’ve created more value than expected. This asymmetry is exactly what disciplined acquirers want.
Before we celebrate Thermo Fisher’s deal, let’s look at what happens when the synergy math is wrong. Because it often is. At least one-third of acquirers destroy value, and the cautionary tales are spectacular.
Kraft-Heinz: The $15.4 Billion Write-Down
When Kraft merged with Heinz in 2015, the plan was simple: apply 3G Capital’s famous cost-cutting playbook. Slash SG&A, close factories, eliminate redundancy. Expected synergies: $1.5 billion.
But cost-cutting has limits. You can’t cut your way to growth. Kraft Heinz slashed R&D and marketing — the very investments that keep brands relevant. Consumer tastes shifted toward healthier, natural foods, and Kraft Heinz’s legacy brands couldn’t keep up.
The result: a $15.4 billion goodwill write-down and a 20% stock price slump. Warren Buffett himself admitted he overpaid. The synergies were real — but the brand deterioration they caused was worse.
HP + Autonomy: The $8.8 Billion Fraud
In 2011, HP paid $11 billion for Autonomy, a British software company. Just one year later, HP wrote down $8.8 billion — destroying 80% of the value.
What happened? HP alleged that Autonomy had inflated its financial numbers before the acquisition — making the company appear more profitable than it actually was. Due diligence failed to catch the deception. The lesson: you can only value what you can verify, and if the numbers are fake, no amount of financial modeling will save you.
Daimler-Benz + Chrysler: Cultural Collision
In 1998, Daimler-Benz and Chrysler announced a “merger of equals” — one of the largest in automotive history. On paper, it made perfect sense: German engineering precision combined with American mass-market reach.
In practice, the cultures collided violently. German executives expected formality, hierarchy, and precision. American executives expected speed, informality, and autonomy. Neither side would bend. Management conflicts paralyzed decision-making.
By 2007, Daimler sold Chrysler for a fraction of what it had paid — a textbook case of negative synergies from cultural conflict. The combination produced outcomes worse than either company would have achieved alone.
The Pattern
Academic research confirms what these cases illustrate: acquirers earn negative returns on average. Why? Empire-building — managers sometimes pursue M&A for size and prestige, not value creation. The acquirer who wins a bidding war is often the one who overvalues the target the most.
Negative synergies can emerge from conflicting corporate cultures, integration challenges, employee resistance, and regulatory issues. This is why Parker’s due diligence process (Part 1) and valuation discipline (Part 2) matter so much — they’re the defense against becoming the next cautionary tale.
(a) Kraft-Heinz — overestimated cost synergies and underestimated brand deterioration. The cost-cutting playbook destroyed the very brands that made the company valuable.
(b) HP-Autonomy — Autonomy inflated its financial numbers. HP’s due diligence failed to catch the deception. No amount of synergy modeling matters if the inputs are fraudulent.
(c) Daimler-Chrysler — German and American corporate cultures clashed, creating negative synergies. The “merger of equals” became a case study in how cultural incompatibility can destroy more value than any synergy can create.
Buying a company is like buying a house in a hot market — except the house has 25,000 residents who can leave anytime, the seller knows you really want it, and you’re negotiating in front of Wall Street. Oh, and every dollar in the offer is multiplied by 346.7 million.
The Thermo Fisher – PPD negotiation played out over seven weeks, across four offers. Each step reveals something about how real M&A negotiations work.
2021
March
2021
2021
Offer 1: $42.25 — “Not Sufficient”
On February 25, 2021, Thermo Fisher made its formal opening bid: $42.25 per share, a 20% premium over PPD’s closing price that day ($35.23). PPD’s response was swift and blunt: “Not a sufficient price level that would justify further engagement.”
Translation: not even worth talking about at that price.
Offer 2: $44.00 — Door Opens
In mid-March, Thermo Fisher came back with $44.00 per share. PPD rejected this too — but something changed. PPD signed a nondisclosure agreement and shared a diligence presentation, discussing the company’s goals and strategic vision with Thermo Fisher management.
The price wasn’t right, but the door was now open.
Offer 3: $47.00 — “Higher”
On March 29, Thermo Fisher jumped to $47.00 per share. PPD’s response was telling: “The price would need to be higher.” Not rejected — just not enough.
Meanwhile, two things happened in parallel. Thermo Fisher continued deep due diligence: site visits, finance discussions, IT assessments. And PPD quietly reached out to four alternative potential acquirers — but all four declined to discuss or pursue a deal.
This was critical information for both sides. PPD now knew it had no alternatives. And Thermo Fisher — if they discovered this — knew they were the only serious suitor.
Offer 4: $47.50 — “Best and Final”
On April 14, Thermo Fisher submitted what it called its “best and final offer”: $47.50 per share. The math:
PPD accepted. The deal was announced the next day, April 15, 2021. PPD’s shares closed at $45.80 (below the offer price, reflecting the time value until close). Thermo Fisher’s shares closed at $494.38.
On December 8, 2021, the acquisition was completed: $17.4 billion in cash, plus approximately $3 billion of PPD’s net debt assumed. Thermo Fisher expected the deal to add $1.40 to adjusted EPS in the first 12 months and realize $125 million in total synergies by end of 2024.
Reverse Engineering the $47.50
Can we justify the $47.50 price with a valuation model? Yes — but it requires aggressive assumptions:
- Sales growth: Must use the company’s optimistic (upside) forecasts
- NOPAT margins: Must assume 15% (vs the 3-year historical average of 7.7%) until terminal value of 7%
- Synergies: Revenue synergies stay the same, but cost synergies must be doubled
The key insight: NOPAT margins needed to be higher than historical margins. PPD had to perform BETTER inside Thermo Fisher than it ever had alone. And there was a trade-off: “Standalone forecasts can be lower if the synergy assumptions are higher.” It’s a system — the pieces have to add up to $47.50, but there are many combinations that work.
Market Reaction
The market reaction was mixed at first. Thermo Fisher had previously stated it wasn’t interested in entering the CRO space, so the announcement surprised many analysts. Skeptics questioned the company’s ability to navigate an unfamiliar business.
But supporters saw the strategic logic: an “industry-first CRO/CDMO combination.” The stock market ultimately reacted positively — Thermo Fisher’s shares rose roughly 35% by the time the deal closed in December 2021.
And Parker had an early win: the original EPS impact projection of +$1.40 was later updated to +$1.90. As Parker put it: “The actual prospects for the company have gone extremely well!”
PPD played the negotiation skillfully:
- Rejected the first two offers to establish that they wouldn’t sell cheap. The first rejection was particularly aggressive: “not sufficient to justify further engagement.”
- Signed the NDA after offer 2 — signaling willingness to engage at the right price. This moved from “we won’t talk” to “we’ll talk if you’re serious.”
- Shopped to 4 alternatives after offer 3 — a standard move to verify they were getting the best deal. When all four declined, PPD confirmed that Thermo Fisher was the best (and only) serious option.
- Accepted $47.50 after confirming no alternatives existed. PPD ultimately got a 35% premium over the initial reference price — up from the 20% that Thermo Fisher first offered.
The negotiation illustrates a key concept: BATNA (Best Alternative To Negotiated Agreement). PPD tried to discover their alternatives — and found they had none. This is actually a weakness in negotiation, but PPD still extracted a significant premium increase from offer 1 to offer 4 (20% → 35%) by playing the process well.
Strategic conviction. Thermo Fisher didn’t walk away because PPD was the best CRO target and filled a critical gap in their drug development platform. After offer 2, PPD opened the NDA and shared diligence materials — signaling willingness to engage at the right price.
The fact that all 4 alternative acquirers declined confirmed PPD had limited options. Parker knew the strategic value was real — it was just a question of finding the right price. Walking away would have meant abandoning the entire CRO/CDMO integration strategy, not just losing one deal.
Note: “emotional commitment” (option A) is actually a common M&A pitfall — but it’s not what happened here. Parker’s process was disciplined and data-driven, not emotional.
When you buy a house for $500K but the land and building are only worth $300K, the extra $200K is what you’re paying for the location, the school district, the neighbors. In M&A, that “extra” has a name: goodwill. And for Thermo Fisher, it was $13.8 billion.
A. The Price Tag Breakdown
Here’s what Thermo Fisher actually paid and what they got for it, straight from the SEC filing (Form 10-K):
But where did $16 billion actually go? The answer reveals something fundamental about modern M&A: you’re not buying factories.
Intangible Assets: What You Can’t Touch
“Intangible” literally means something you cannot touch. Patents, trademarks, customer lists, brand names — they have enormous value but no physical form.
Here’s the accounting quirk that makes M&A interesting: when a company builds intangible assets internally (like R&D or brand reputation), those costs are expensed — they don’t appear as assets on the balance sheet. But when you acquire intangible assets by buying another company, they’re recorded at their purchase price as assets on the balance sheet.
This is why M&A “creates” assets that didn’t exist before. PPD’s customer relationships were always valuable — they just weren’t on anyone’s balance sheet until Thermo Fisher bought them.
Why Customer Relationships = $6.3 Billion
PPD served all of the top 50 global biopharma companies. Thermo Fisher planned to cross-sell its full suite of services to PPD’s existing clients. As the company explained: “An asset is defined as a source of future value. Clearly, PPD’s existing customers would bring future value.”
To value these relationships, Thermo Fisher used “projections of cash flows that will arise from identifiable intangible assets” with “estimates of customer attrition and technology obsolescence rates.”
The result: $6.264 billion in customer relationships, amortized over 17 years. That means Thermo Fisher believes these customer relationships will generate value for nearly two more decades.
Goodwill: $13.8 Billion
Goodwill is the amount paid above the assessed fair value of all identifiable assets. It’s the catch-all for everything that makes the company valuable but can’t be specifically identified — the assembled workforce, the brand synergy, future growth potential, the strategic position.
Unlike customer relationships and tradenames (which are amortized over their useful life), goodwill is not amortized under US GAAP. Instead, it’s tested annually for impairment. If the deal turns bad, goodwill gets written down — just like HP’s $8.8 billion Autonomy write-down from Part 5.
The impact on Thermo Fisher’s balance sheet was massive: total assets increased by approximately 29%.
Intangible assets are specifically identifiable sources of value:
- Customer relationships — valued at $6.3B, amortized over 17 years
- Tradenames — valued at $603M, amortized over their useful life
- Backlog — valued at $1.1B, representing contracted but undelivered work
- Patents, technology — specific IP with identifiable value
Goodwill is the catch-all for everything above identifiable assets:
- Assembled workforce value (talented scientists, experienced managers)
- Brand synergies and strategic positioning
- Future growth potential beyond current contracts
- The value of being part of a larger organization
Key differences:
- Intangibles are amortized (expense spread over useful life). Goodwill is not amortized but tested annually for impairment.
- Both are created only through acquisition — you can’t put your own brand reputation on your balance sheet. PPD’s customer relationships were always valuable, but they only appeared as a $6.3B asset after Thermo Fisher bought them.
- If the deal goes bad, goodwill gets written down (impaired). If an intangible asset becomes worthless (e.g., customers leave), it gets written off too.
Most of the purchase price went to goodwill ($13.8B) and identifiable intangible assets — customer relationships ($6.3B), tradenames ($603M), and backlog ($1.1B) — minus assumed liabilities ($9.6B in debt, deferred taxes, contracts, and other liabilities).
This reflects that PPD’s value wasn’t in its buildings and equipment — it was in its people, customer relationships, and industry position. When you buy a service company, you’re buying intangibles. The goodwill figure doesn’t mean Thermo Fisher overpaid — it means most of PPD’s value is in things you can’t physically touch.
B. The “New” Thermo Fisher — Before vs After
So what happened to Thermo Fisher’s financial profile after absorbing a $17.4 billion acquisition? The numbers tell a story of short-term pain for long-term gain.
Why RNOA Dropped
The biggest change in Thermo Fisher’s assets wasn’t from PP&E (there were only minor additions of physical equipment). It was from intangible assets of over $20 billion and goodwill of $13.8 billion added to non-current assets.
Annualized RNOA decreased from 15.6% to 12.5% because the increase in assets (the denominator) outweighed the increase in profits (the numerator) in the first quarter after acquisition. Assets jumped immediately; synergies take years to materialize.
Why Debt More Than Doubled
Thermo Fisher financed the acquisition mostly with cash and new debt. PPD shareholders received only $43 million in Thermo Fisher shares — this was overwhelmingly a cash deal. Debt went from $13.7B to $35.2B, increasing 2.5 times.
The increase in leverage cuts both ways. On the upside: “It now has the potential to provide higher returns to shareholders on each dollar of equity.” On the downside: “As financial leverage increases, so does the financial risk” — the company has to service its debt even in bad times.
The Silver Lining: Gain on Financial Leverage
Here’s the nuance: the gain on financial leverage increased from 4.54% to 9.16%. Thermo Fisher was not highly leveraged before the deal. Taking on debt at a cost below its RNOA means each dollar of equity now generates higher returns. More leverage + a positive spread = amplified returns for shareholders.
But this works in reverse too. If performance declines and the spread turns negative, the same leverage amplifies losses. Investors must judge whether PPD’s revenue and earnings potential justify the increase in financial risk.
In every large acquisition, the pattern is the same: RNOA drops in the short term and (if the deal works) recovers over the medium term.
Why it drops: Goodwill and intangible assets inflate the asset base immediately — the day the deal closes, $20B+ in new assets appear on the balance sheet. But the synergies that justify those assets take 2–3 years to materialize. The numerator (profit) lags the denominator (assets).
Why it recovers: As the source material explains: “It is the realization of synergies, economies of scale, and the growth of the business that enhances the business in the medium and long term and that allows for key financial metrics to improve and surpass those of the pre-acquisition company.”
Analogy: Think of buying a house that needs renovation. The day you buy it, your ROI looks terrible — you paid full price but haven’t done any work yet. After the renovation, the house is worth more than you paid. The initial ROI dip is the cost of entry; the recovery is the reward for executing well.
The question isn’t whether RNOA dropped — it always does after a major acquisition. The question is whether it recovers as synergies kick in.
No, this is expected. Goodwill ($13.8B) and intangible assets ($20B+) inflated the asset base immediately, while synergies take 2–3 years to materialize. The denominator grew faster than the numerator.
The real question isn’t whether RNOA dropped — it always does after a major acquisition. The question is whether it recovers and eventually exceeds pre-acquisition levels as synergies kick in. For Thermo Fisher, the early evidence (which we’ll see in Part 8) was positive.
We’ve valued PPD, calculated synergies, watched four rounds of negotiation, seen $13.8 billion in goodwill created, and watched RNOA drop 3 points. Now for the question that matters: was it worth it?
A. The Analyst Scoreboard
Let’s check what Wall Street analysts said at three time points after the acquisition closed.
The verdict from the source material: “These accounts suggest that the PPD acquisition was a good strategic decision by Thermo Fisher.”
PPD was growing faster than the CRO market, the end-to-end offering was resonating with customers, and the financial performance exceeded original projections. Parker’s EPS impact estimate increased from +$1.40 to +$1.90. As he put it: “The actual prospects for the company have gone extremely well!”
B. Parker’s Five Pitfalls to Avoid
With decades of M&A experience, Parker identifies five common pitfalls that derail acquisitions. As he frames it: “M&A is, by nature, distracting and disruptive — both to the target and also, in many cases, to the acquiring company. A meaningful transaction may be the one corporate event that happens every decade to a company.”
C. Five Best Practices from Decades of Deal-Making
Beyond avoiding pitfalls, Parker shares five practices that have guided successful deals throughout his career:
On the nature of M&A: “M&A is, by nature, disruptive — both to the target and also, in many cases, to the acquiring company. A meaningful transaction may be the one corporate event that happens every decade to a company, and so feeling comfortable that you can approach an entity and acquire it, value it properly, and integrate it, that’s pretty challenging.”
On talent retention: “Talent retention is always at the top of the list. Obviously, talent across the entire organization is critical but really identifying early who the most important people to retain are and how you’re going to do that.”
On integration vs. the deal: “A lot of time is spent in M&A transactions thinking about the deal, the negotiations, the execution, the timing, the market. All of those things create this beehive of activity and a number of people getting involved that are then very focused on the outcome of announcing a transaction or closing a transaction when the real outcome is about integrating the company into your business successfully. The critical element is to make sure that you spend enough time up front before you announce a deal, thinking about what your plan is going to be, to actually successfully close and then integrate the company.”
On management bandwidth: “Management bandwidth in doing M&A transactions is a challenge. And I think that’s where some companies, particularly who don’t do this very often, find one of the bigger pitfalls that they don’t estimate enough, how much time is involved in actually concluding and conducting a transaction.”
On staying close to core: “There’s often a lack of connectivity to the company. If you’re assessing something too far afield that can create an issue where you may or may not have the right kind of management capability internally. And so it’s important to make sure do you have the right kind of advisers, or should you not look too far afield from your own core business.”
On due diligence as integration planning: “Due diligence isn’t just about finding the challenging gotchas, but it really is also about how am I going to bring this company into my company and think about it from an integration point of view. So making sure that you really understand their HR policies, their real estate policies, their accounting policies, tax, legal, cyber, IT, et cetera. All of those things.”
On being pragmatic: “Deals are done in a very specific context. Each one is truly specific and bespoke to the circumstances you have at the time.”
On being nimble: “Projections are done with folks sitting around a table, but the inputs are supplied by circumstances and individuals. So, you have to be able to get out of the details, step back, and ask, ‘Does this make sense?’”
On being prepared: “A lot can be done before you approach a company, and, in many cases, the outcome will be that you don’t approach the company. You determine that this is not a deal you should do. The most important transactions that are considered are the ones that you don’t do.”
On the human element: “You’re negotiating with humans. Transactions are disruptive by nature and have an impact on the individual receiving the offer. They may lose their job, they may have a very different job on the outcome, or the business that they’ve known is going to change. As an acquirer, you should approach your interactions with sensitivity to understand the dynamics. Try to do no harm and make sure that companies and management teams on the other side feel respected.”
On win-win outcomes: “In a win-win situation, you’re going to have better long-term prospects in the combination, where the people who are joining your company, your new colleagues, are going to feel much better about your own company.”
Module Wrap-Up
Posts 8 and 9 covered the complete M&A lifecycle: why companies merge → synergy types → deal classification → strategic rationale → due diligence → valuation → synergy math → negotiation → goodwill & intangibles → post-merger impact → the verdict.
The Thermo Fisher + PPD story illustrates every concept: from “we’ll never do CRO” to a $17.4B bet that — by all early evidence — paid off.
The key takeaway: “A good strategist should strive to align every part of their organization to create a whole that is greater than the sum of the parts.” Thermo Fisher didn’t just buy PPD — they integrated PPD into a platform where the combination creates value that neither company could achieve alone.
You’re valuing an acquisition target. Standalone intrinsic value: $40/share. Synergies worth $8/share. Market price: $35/share. Your offer: $47.50/share.
What’s the acquisition premium? What’s the value created? Is the deal worth it?
Acquisition premium: $47.50 − $35 = $12.50 per share (35.7% premium).
Value received: $40 (intrinsic) + $8 (synergies) = $48 per share.
Value created: ($48 − $47.50) / $47.50 = 1.1%.
The deal technically creates positive value — but barely. A razor-thin 1.1% margin means any underperformance on synergies destroys value. If synergies come in at $7 instead of $8, value created goes to ($47 − $47.50) / $47.50 = −1.1%. This is why Parker insists on conservative synergy estimates and aggressive sensitivity testing.
Company A acquires Company B for $10B. Company B’s identifiable assets are worth $6B and liabilities are $3B (net assets = $3B).
How much goodwill is created? If 2 years later the acquired business is only worth $5B, what happens to goodwill?
Goodwill created: $10B (price paid) − $3B (net identifiable assets) = $7B in goodwill.
If business is now worth $5B: Total carrying value is $10B ($3B net assets + $7B goodwill). But the business is only worth $5B. Goodwill must be impaired (written down) by at least $5B — goodwill drops from $7B to $2B.
This $5B write-down hits the income statement as a loss. It’s exactly what happened to HP with Autonomy ($8.8B write-down) and Kraft-Heinz ($15.4B write-down). Goodwill impairment is the accounting reckoning for overpaying.
A company’s pre-acquisition RNOA is 16%. After acquiring a target for 3× net asset value, RNOA drops to 11%. The CEO says: “Don’t worry, this is normal.”
Three years later, RNOA is 14%. Has the acquisition been successful?
The CEO is right that the initial drop is normal — goodwill from paying 3× net asset value inflates the denominator immediately while synergies take years to materialize. This is exactly what happened to Thermo Fisher (15.6% → 12.5%).
At 14% after 3 years, RNOA hasn’t fully recovered to the pre-acquisition 16%, but it’s trending upward. Whether the deal is “successful” depends on:
- (a) Is 14% above the cost of capital? If so, the acquisition is generating positive economic value.
- (b) Are synergies still materializing? If the trajectory is upward, more gains may be coming.
- (c) What’s the comparison? 14% post-acquisition may be better than the 16% would have been without the deal if the base business was declining.
The honest answer: it’s “promising but not proven.” Not a clear success, not a failure — exactly the gray zone where most real M&A outcomes live.
You’re the CFO of PPD. Thermo Fisher offers $42.25/share (20% premium). Your stock is at $35. You’ve been growing at 12–16% and you know your CRO position is strong.
What’s your counter-strategy? (Reject outright? Counter-offer? Shop to competitors? Accept?)
PPD’s actual strategy: reject, but keep the door open.
- Rejected the first offer aggressively (“not sufficient to justify further engagement”) to anchor negotiations higher.
- Rejected the second offer ($44) but signed an NDA and shared diligence materials — signaling willingness to engage at the right price.
- After the third offer ($47), shopped to 4 alternative acquirers. All declined. This confirmed Thermo Fisher was the best option — but also revealed PPD had no BATNA (Best Alternative To Negotiated Agreement).
- Accepted $47.50 as “best and final offer.” Premium increased from 20% to 35%.
Key lesson: Knowing your BATNA is critical. PPD discovered they had no real alternatives, which ultimately led them to accept offer 4 rather than risk Thermo Fisher walking away. But by playing the process skillfully — rejecting early, engaging gradually, and testing alternatives — PPD extracted a 75% increase in the premium (from 20% to 35%).